Movement Alert|Moderna, Inc. Falls 3.19% in Regular Trading, Morgan Stanley Raises Target but Caution on Spending and Execution Persists

Market Focus11-17

On November 17, Moderna, Inc. fell 3.19% in Regular Trading, trading around $209.315 per share, with turnover of $173 million.

The key catalyst was Morgan Stanley’s decision to raise its price target to $200 from $95 while maintaining an Equal Weight rating, a move that still left the stock above the revised target and reinforced a cautious market stance on near-term upside.

Background updates from the company’s recent analyst day showed expected year-end total liquidity of about $9 billion, projected 2027 cash costs of about $4 billion, an extension of its $1.5 billion credit facility to 2031, and a higher revenue growth outlook of 15% to 25%. Even so, recent trading suggests investors remain focused on oncology investment intensity, cost discipline, and execution pacing, limiting enthusiasm despite improved financial planning and prior better-than-expected quarterly results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment